BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21155942)

  • 1. Perspective on prostate cancer screening.
    Rogers CS
    Int J Clin Pract; 2011 Jan; 65(1):31-4. PubMed ID: 21155942
    [No Abstract]   [Full Text] [Related]  

  • 2. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
    Mian BM
    Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 5. Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?
    Otto SJ; van Leeuwen PJ; Hoekstra JW; Merckelbach JW; Blom JH; Schröder FH; Roobol MJ; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3061-7. PubMed ID: 21047587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epilogue: different approaches for prostate cancer screening in the EU?
    Schröder FH; Denis L; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phantom menace of prostate cancer screening.
    Ghani KR; Trinh QD; Menon M
    BJU Int; 2012 Feb; 109(3):324-6. PubMed ID: 22243666
    [No Abstract]   [Full Text] [Related]  

  • 8. Two randomized screening trials with prostate cancer mortality, two interim results: a consideration of usual-care window in screening trials.
    Song Y
    Contemp Clin Trials; 2010 Jul; 31(4):378-80. PubMed ID: 20450987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 11. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer.
    Schröder FH
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S164-70. PubMed ID: 21943970
    [No Abstract]   [Full Text] [Related]  

  • 13. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for prostate cancer.
    Croswell J; Shin YR
    Am Fam Physician; 2013 Feb; 87(4):283-4. PubMed ID: 23418805
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.
    Laurila M; van der Kwast T; Bubendorf L; di Lollo S; Pihl CG; Ciatto S; Hugosson J; Määttänen L; Roobol MJ; Kujala PM
    Eur J Cancer; 2010 Nov; 46(17):3068-72. PubMed ID: 21047588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50".
    Andriole GL; Kibel AS
    Cancer; 2011 Mar; 117(6):1110-2. PubMed ID: 20960524
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen - useful screening tool or potential liability?
    Mahar P; Sengupta S; Ludlow K; Corcoran N
    Aust Fam Physician; 2010 Aug; 39(8):598-600. PubMed ID: 20877758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.